drugset
drugset / Trial / NCT00381615

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

NCT00381615 ↗

Phase 2 Completed 147 enrolled Novartis Vaccines
RandomizedParallel-groupOpen-labelPrevention

Summary

This study was aimed to explore safety and immunogenicity of two formulations of a Meningococcal B Vaccine when administered to healthy infants.

Timeline

Start
2006-09
Primary completion
2007-07
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject rMenB Vaccine 0.5 ml —
Subject rMenB+OMV Vaccine 0.5 ml —
Background DTaP-Hib-IPV Vaccine 0.5 ml Intramuscular
Background MMR Vaccine 0.5 ml Intramuscular
Background MenC-Hib Vaccine 0.5 ml Intramuscular
Background Menjugate Vaccine 0.5 ml Intramuscular
Background PC7 Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.